Related Experiment Video
Updated: May 8, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Biomarkers of Alzheimer's disease: the present and the future
S Lehmann1, C Delaby, J Touchon
1Laboratoire de biochimie protéomique clinique et CCBHM, hôpital Saint-Éloi, institut de recherche en biothérapie, CHU de Montpellier, 80, avenue A.-Fliche, 34295 Montpellier cedex 5, France; Inserm U1040, université Montpellier 1, 80, avenue A.-Fliche, 34295 Montpellier cedex 5, France.
Abstract:
A paradigm shift has occurred in the last ten years in the diagnostic field of Alzheimer's disease (AD). Scientific thought has enriched the concept of AD as a pathophysiological continuum and emphasized contribution of biological, morphological and functional brain imaging biomarkers for diagnosis, in particular during the early stages of the disease. We address here the present and the future of these biological biomarkers. Most of them are linked to the pathophysiological lesions of the Alzheimer process: aggregates of hyperphosphorylated tau proteins, also called neurofibrillary tangles (NFT), and extracellular deposit of amyloid-beta peptides (Aβ), also called senile plaques. The detection in the cerebrospinal fluid (CSF) of tau and Aβ represents the current diagnostic practice of AD. Improvement for a more accurate and earlier biological diagnosis is however expected using a new generation of biomarkers, mostly in relation with tau and Aβ metabolism.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Dementia l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual.
